Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial-Reference-Cited by-同舟云学术

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

Published:2024-06 Issue:6 Volume:11 Page:e369-e379
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Molina Jean-Michel,Rizzardini Giuliano,Orrell Catherine,Afani Alejandro,Calmy Alexandra,Oka Shinichi,Hinestrosa Federico,Kumar Princy,Tebas Pablo,Walmsley Sharon,Grandhi Anjana,Klopfer Stephanie,Gendrano Isaias,Eves Karen,Correll Todd A,Fox Michelle C,Kim Jason

Funder

Merck Sharp and Dohme United Kingdom

Merck

Publisher

Elsevier BV

Reference27 articles.

1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA panel;Saag;JAMA,2020

2. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Cadiñanos;Expert Opin Drug Saf,2021

3. Rational design of doravirine: from bench to patients;Hwang;ACS Infect Dis,2020

4. Clinical pharmacokinetics of the novel HIV-1 non-nucleoside reverse transcriptase inhibitor doravirine: an assessment of the effect of patient characteristics and drug-drug interactions;Khalilieh;Clin Drug Investig,2020

5. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial;Molina;Lancet HIV,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Pipeline of Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

2. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial;The Lancet HIV;2024-06

3. Is this the end of the road for daily islatravir 0·75 mg?;The Lancet HIV;2024-06